N

    NeoGenomics Inc (NEO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $17.91
    -0.14 (-0.78%)

    Market Cap: $2.30B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    -25.13%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.05
    Range$0.04 - $0.07
    10 analysts
    EPS Revisions
    2
    0
    7d
    2
    3
    30d
    EPS Estimate Drift
    90d ago$0.06+7.7%
    60d ago$0.06+7.7%
    30d ago$0.06+7.7%
    7d ago$0.05+3.1%
    Current$0.05
    Revenue Consensus
    $206M
    Range$204M - $207M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.09
    Range$0.07 - $0.11
    11 analysts
    Revenue Consensus
    $217M
    Range$212M - $218M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.09---
    Sep 26EST
    		-$0.05---
    Jun 26
    Reported Jul 28
    		$-0.01N/A+83.33%Beat-133.3%
    Mar 26
    Reported Apr 28
    		$0.01$0.01-12.28%Miss+104.9%
    Dec 25
    Reported Feb 17
    		$0.06$0.04+50.00%Beat+50.0%
    Sep 25
    Reported Oct 28
    		$0.03$0.02+50.00%Beat+121.5%
    Jun 25
    Reported Jul 29
    		$0.03$0.02+50.00%Beat+0.0%
    Mar 25
    Reported Apr 29
    		$-0.20$-0.01-1935.00%Miss-917.5%
    Dec 24
    Reported Feb 18
    		$0.04$0.03+39.86%Beat+33.3%
    Sep 24
    Reported Nov 5
    		$-0.14$0.01-1494.00%Miss-597.0%
    Jun 24
    Reported Jul 29
    		$0.03$-0.00+1404.35%Beat+160.0%
    Mar 24
    Reported Apr 30
    		$-0.02N/A+60.00%Beat+77.8%
    Dec 23
    Reported Feb 20
    		$0.03$-0.03+200.00%Beat+150.0%
    Sep 23
    Reported Nov 6
    		$-0.02N/A+75.00%Beat+85.7%
    Jun 23
    Reported Aug 8
    		$-0.05N/A+54.55%Beat+68.8%
    Mar 23
    Reported May 8
    		$-0.09$-0.15+40.00%Beat+55.0%
    Dec 22
    Reported Feb 23
    		$-0.06N/A+62.50%Beat+57.1%
    Sep 22
    Reported Nov 8
    		$-0.14$-0.21+33.33%Beat-75.0%
    Jun 22
    Reported Aug 9
    		$-0.16$-0.23+30.43%Beat-1500.0%
    Mar 22
    Reported Apr 27
    		$-0.20$-0.24+16.67%Beat-400.0%
    Dec 21
    Reported Feb 23
    		$-0.14$-0.15+6.67%Beat-200.0%
    Sep 21
    Reported Nov 4
    		$-0.08$-0.09+11.11%Beat-233.3%
    Jun 21
    Reported Aug 6
    		$-0.01N/A+83.33%Beat+75.0%
    Mar 21
    Reported May 5
    		$-0.04$0.01-500.00%Miss-100.0%
    Dec 20
    Reported Feb 24
    		$0.14$0.06+133.33%Beat+40.0%
    Sep 20
    Reported Oct 27
    		$0.06$0.04+50.00%Beat-14.3%
    Jun 20
    Reported Jul 28
    		$-0.04N/A+60.00%Beat-157.1%
    Mar 20
    Reported Apr 28
    		$-0.02$0.02-200.00%Miss-128.6%
    Dec 19
    Reported Feb 27
    		$0.10$0.06+66.67%Beat+66.7%
    Sep 19
    Reported Oct 29
    		$0.07$0.06+16.67%Beat+40.0%
    Jun 19
    Reported Jul 30
    		$0.07$0.06+16.67%Beat+40.0%
    Mar 19
    Reported Apr 30
    		$0.07$0.04+75.00%Beat+75.0%
    Dec 18
    Reported Feb 19
    		$0.06$0.04+50.00%Beat+20.0%
    Sep 18
    Reported Oct 30
    		$0.05$0.02+150.00%Beat+400.0%
    Jun 18
    Reported Jul 24
    		$0.05$0.04+25.00%Beat+25.0%
    Mar 18
    Reported May 1
    		$0.04$0.03+33.33%Beat+33.3%
    Dec 17
    Reported Feb 21
    		$0.05$0.04+25.00%Beat+0.0%
    Sep 17
    Reported Oct 25
    		$0.01$0.02-50.00%Miss-75.0%
    Jun 17
    Reported Jul 25
    		$0.04$0.03+33.33%Beat-
    Mar 17
    Reported Apr 26
    		$0.03$0.03+0.00%Beat-
    Dec 16
    Reported Feb 22
    		$0.05$0.03+66.67%Beat-
    Sep 16
    Reported Oct 26
    		$0.04$0.03+33.33%Beat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%
    FrequencySpecial
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio199.00EV/EBITDA199.99x
    Price/FCF-63.72xFCF Yield-1.57%
    Profitability
    Profit Margin-6.77%Operating Margin-4.84%
    ROE-6.33%ROIC-4.29%
    Financial Health
    Debt/Equity0.48xInterest Coverage-20.37x
    Current Ratio3.60xQuick Ratio3.35x
    Trading Statistics
    Beta1.73Avg Volume1.85M
    52-Week High$19.7652-Week Low$7.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.12
    SMA 20$16.67
    SMA 50$15.21
    SMA 200$11.52
    EMA 10$17.31
    EMA 20$16.67
    EMA 50$15.10
    EMA 200$11.89

    MACD

    Line: 0.83Signal: 0.74Hist: 0.09

    ADX

    ADX: 44.8+DI: 36.1-DI: 12.0

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down4.0
    PSAR$19.76

    Bollinger Bands

    Upper Band$18.25
    Lower Band$15.09
    %B Position1893%(Upper)
    Band Width0.89

    RSI (14-Day)

    Neutral
    63.7

    Momentum Oscillators

    Stoch %K61.4
    Stoch %D73.2
    Williams %R-45.8
    ROC (10d)10.8%
    Momentum1.75
    CCI (20d)133.1
    MFI (14d)56.4

    Volatility Measures

    ATR (14d)$0.84(4.7%)
    StdDev (20d)0.79
    Hist Vol50.3%(High)

    Volume Flow

    VWAP$17.73
    OBV100.4M
    AD Line26.1M
    CMF (20d)0.064

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.9x
    VWMA (20d)$16.87

    Pivot Points

    R3$19.42
    R2$19.09
    R1$18.57
    Pivot Point$18.23
    S1$17.71
    S2$17.38
    S3$16.86

    Advanced Oscillators

    TSI27.30
    Ultimate Osc58.7
    KST142.24

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$201.66M$186.67M$190.17M$187.80M$181.33M$168.03M$172.00M$167.82M$164.50M$156.24M$155.55M$151.95M
    Cost of Revenue$109.78M$105.81M$114.46M$107.35M$104.07M$94.79M$94.74M$92.94M$92.01M$90.77M$87.96M$89.64M
    Gross Profit$91.88M$80.86M$75.71M$80.45M$77.26M$73.25M$77.26M$74.88M$72.49M$65.47M$67.59M$62.31M
    Operating Expenses$101.65M$99.11M$86.85M$107.46M$124.89M$101.07M$95.66M$96.08M$94.44M$96.04M$86.16M$86.51M
    R&D$10.76M$9.53M$9.18M$8.69M$9.02M$10.18M$7.97M$7.68M$7.89M$7.62M$7.13M$5.29M
    SG&A$63.61M$65.74M$63.51M$69.87M$71.75M$65.22M$63.64M$66.97M$63.33M$65.80M$59.76M$61.49M
    Operating Income$-9,771,000$-18,241,000$-11,141,000$-27,014,000$-47,628,000$-27,825,000$-18,401,000$-21,197,000$-21,941,000$-30,567,000$-18,574,000$-24,195,000
    Interest Income$1.21M$1.27M$1.52M$1.56M$2.26M$3.72M$4.33M$4.67M$4.59M$4.83M$10.07M$2.84M
    Interest Expense$781,000$598,000$599,000$603,000$933,000$1.62M$1.62M$1.64M$1.67M$1.69M$1.68M$1.69M
    Income Before Tax$1.83M$-17,578,000$-12,406,000$-26,389,000$-45,816,000$-25,657,000$-16,128,000$-17,849,000$-19,017,000$-27,681,000$-15,286,000$-21,451,000
    Income Tax Expense$-412,000$-472,000$-2,525,000$740,000$-724,000$266,000$-804,000$-150,000$-375,000$-620,000$-960,000$-2,935,000
    Net Income$2.24M$-17,106,000$-9,881,000$-27,129,000$-45,092,000$-25,923,000$-15,324,000$-17,699,000$-18,642,000$-27,061,000$-14,326,000$-18,516,000
    EBITDA$18.82M$-567,000$4.59M$-9,952,000$-27,619,000$-6,311,000$3.68M$1.78M$756,000$-7,729,000$4.76M$-1,633,000
    EBIT$2.61M$-16,980,000$-11,807,000$-26,389,000$-44,883,000$-24,039,000$-14,504,000$-16,207,000$-17,351,000$-25,996,000$-13,605,000$-19,766,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NEO

    Government Contracts

    Gov Obligations (TTM)
    $2.60M
    Gov Obligations / Revenue
    0.3%
    Obligations YoY
    5.2%
    Active Awards
    17
    New Awards (TTM)
    8
    Avg Remaining Term
    6.2 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25726N0072Department of Veterans AffairsDepartment of Veterans Affairs$2.79MJan 1, 2026
    36C26126N0417Department of Veterans AffairsDepartment of Veterans Affairs$643694Apr 26, 2026
    36C24126N0285Department of Veterans AffairsDepartment of Veterans Affairs$500000Apr 1, 2026
    36C25726N0390Department of Veterans AffairsDepartment of Veterans Affairs$493650Jul 1, 2026
    75H71226F28001Department of Health and Human ServicesIndian Health Service$401779Jun 1, 2026
    36C26126N0169Department of Veterans AffairsDepartment of Veterans Affairs$325000Oct 26, 2025
    36C25926N0228Department of Veterans AffairsDepartment of Veterans Affairs$100000Jul 1, 2026
    36C24826N0008Department of Veterans AffairsDepartment of Veterans Affairs$10000Oct 1, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    NeoGenomics (NEO) COO converts 28K stock units into common shares

    NeoGenomics (NEO) COO Warren Stone exercised 28,106 Restricted Stock Units (RSUs) into common shares on August 21, 2026, with 11,060 shares subsequently delivered or withheld for tax liabilities. This transaction is detailed in a recent Form 4 SEC filing, which also outlines Stone's remaining equity incentives, including various tranches of stock options, RSUs, and performance stock units. The filing provides comprehensive footnotes explaining the vesting schedules and performance criteria for these equity awards.

    Stock Titan•8/25/26•
    Neutral

    Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST

    NeoGenomics recently secured a significant court victory against Natera, invalidating key patents and reducing legal hurdles for its RaDaR ST assay. This ruling is expected to enhance RaDaR ST's competitive position in molecular residual disease testing and strengthen NeoGenomics' oncology test menu. Despite current losses, the company aims for consistent earnings growth through its expanded offerings, including the PanTracer liquid biopsy and PanTracer Pro portfolio.

    Simply Wall Street•8/25/26•
    Neutral

    Neogenomics stock hits 52-week high at 16.93 USD By Investing.com

    NeoGenomics Inc. stock has reached a new 52-week high of $16.93, with shares currently trading at $16.98, reflecting a 1-year change of 154.81% and an actual 1-year return of 167.48%. Despite being deemed overvalued by InvestingPro analysis, the company reported strong Q2 2026 earnings, surpassing Wall Street expectations, leading Needham to raise its price target to $19.00. The company also announced the upcoming departure of its Executive Vice President and General Counsel, Alicia Olivo.

    Investing.com Nigeria•8/22/26•
    Bullish

    NeoGenomics Inc (NEO) Stock Price, Quote, News & History

    This page provides comprehensive information on NeoGenomics Inc (NEO) stock, including its current price, key statistics, recent news, financial data, and analyst forecasts. As of August 21, 2026, NEO closed at $16.98, with after-hours trading at $17.07, and has recently seen news about a court win regarding Natera patents. The company operates in the Health Care Providers & Services industry, offering oncology diagnostic testing.

    Benzinga•8/22/26•
    Neutral

    Neogenomics stock hits 52-week high at 16.93 USD

    NeoGenomics Inc. (NEO) stock has reached a new 52-week high of $16.93, currently trading at $16.98, reflecting a robust 1-year change of 154.81% and an actual 1-year return of 167.48%. Despite being considered overvalued by InvestingPro, the company recently surpassed Q2 2026 earnings expectations and raised its full-year guidance, leading Needham to increase its price target to $19.00. The stock, however, carries a high beta of 1.73, indicating significant volatility.

    Investing.com•8/21/26•
    Bullish

    Frequently Asked Questions About NEO

    Does NEO pay dividends?
    NeoGenomics Inc (NEO) has a dividend payment track record. See the NEO dividend history page for its current payment status, yield, and streaks.
    What is NEO's P/E ratio?
    NeoGenomics Inc has a price-to-earnings (P/E) ratio of 199.00.
    What is NEO's market cap?
    NeoGenomics Inc (NEO) has a market capitalization of $2.30B with a current stock price of $17.91.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In